首页|Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
To explore the impact of ursodeoxycholic acid(UDCA)on severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and clinical outcomes in patients with autoimmune liver disease(AILD).Patients diag-nosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment.Relevant data were collected regarding AILD diagnosis,treatment,biochemical indi-cators,and imaging examination.The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed.A total of 1,138 patients completed follow-up.The usage rate of hormone(P=0.003)and immunosuppressant(P=0.001)used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group.The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in unin-fected patients(P=0.003).The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group(P=0.018).Logistic regression analysis showed that UDCA use(P=0.003)was cor-related to a lower incidence of SARS-CoV-2,while immunosuppressant use(P=0.017)increased the inci-dence.Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group(P=0.018).UDCA is associated with low SARS-CoV-2 incidence in AILD patients,while immunosuppressant increases its incidence instead.Patients receiving UDCA treatment have a longer recovery time after being infected.

Ursodeoxycholic acid(UDCA)Autoimmune liver disease(AILD)Coronavirus disease 2019(COVID-19)Primary biliary cholangitis(PBC)Autoimmune hepatitis(AIH)

Minghui Li、Weihua Cao、Tingting Jiang、Wen Deng、Shiyu Wang、Shuling Wu、Lu Zhang、Yao Lu、Min Chang、Ruyu Liu、Xiaoyan Ding、Ge Shen、Yuanjiao Gao、Hongxiao Hao、Xiaoxue Chen、Leiping Hu、Mengjiao Xu、Yuyong Jiang、Wei Yi、Yao Xie、Rui Song

展开 >

Department of Hepatology Division 2,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

Department of Hepatology Division 2,Peking University Ditan Teaching Hospital,Beijing 100015,China

Department of Medical Oncology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

Center of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

Department of Gynecology and Obstetrics,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

Department of Infectious Disease,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

展开 >

National Key Research and Development ProgramNational Key Research and Development ProgramBeijing Municipal Health Commission highlevel public health technical personnel construction projectBeijing Hospitals Authority Clinical medicine Development of special funding supportcapital health research and development of special public health projectDigestive Medical Coordinated Development Center of Beijing Hospitals Authority

2022YFC26035002022YFC2603505discipline leader-03-26XMLX 2021272022-1-2172XXZ0302

2024

10.1016/j.bsheal.2024.04.004

生物安全与健康 (英文)
中华医学会

生物安全与健康 (英文)

CSTPCD
ISSN：2096-6962
年,卷(期)：2024.6(3)
  • 2